drugset / Trial / NCT04842045

Pilot RECAP Study in Healthy Volunteers

NCT04842045

Phase 1 Completed 8 enrolled University of Wisconsin, Madison
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of the RECAP Study Program is to investigate the role played by conscious experience in the antidepressant effects of the psychedelic agent psilocybin. This pilot dosing study (PILOT RECAP) is designed to determine the optimal dose of midazolam that allows a psychedelic experience to occur while inducing amnesia for the experience. This is an essential step required for subsequent evaluation of the role of memory for the psychedelic experience in the antidepressant effects of psilocybin in the full RECAP study.

Timeline

Start
2021-05-21
Primary completion
2022-11-17
Completion
2022-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule Intravenous
Subject Psilocybin Other / unclassified 25 mg

Indications